|
1
|
Eaton BR, Schwarz R, Vatner R, Yeh B,
Claude L, Indelicato DJ and Laack N: Osteosarcoma. Pediatr Blood
Cancer. 68 (Suppl 2):e283522021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sadykova LR, Ntekim AI, Muyangwa-Semenova
M, Rutland CS, Jeyapalan JN, Blatt N and Rizvanov AA: Epidemiology
and risk factors of osteosarcoma. Cancer Invest. 38:259–269. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bishop MW, Janeway KA and Gorlick R:
Future directions in the treatment of osteosarcoma. Curr Opin
Pediatr. 28:26–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Knott MM, Hölting TL, Ohmura S, Kirchner
T, Cidre-Aranaz F and Grünewald TG: Targeting the undruggable:
Exploiting neomorphic features of fusion oncoproteins in childhood
sarcomas for innovative therapies. Cancer Metastasis Rev.
38:625–642. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glover J, Man TK, Barkauskas DA, Hall D,
Tello T, Sullivan MB, Gorlick R, Janeway K, Grier H, Lau C, et al:
Osteosarcoma enters a post genomic era with in silico
opportunities: Generation of the High Dimensional Database for
facilitating sarcoma biology research: A report from the Children's
Oncology Group and the QuadW Foundation. PLoS One. 12:e01812042017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:E5564–E5573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lengauer C, Kinzler KW and Vogelstein B:
Genetic instabilities in human cancers. Nature. 396:643–649. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carter SL, Eklund AC, Kohane IS, Harris LN
and Szallasi Z: A signature of chromosomal instability inferred
from gene expression profiles predicts clinical outcome in multiple
human cancers. Nat Genet. 38:1043–1048. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wieczorek M, Bechstedt S, Chaaban S and
Brouhard GJ: Microtubule-associated proteins control the kinetics
of microtubule nucleation. Nat Cell Biol. 17:907–916. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taherdangkoo K, Kazemi Nezhad SR, Hajjari
MR and Tahmasebi Birgani M: miR-485-3p suppresses colorectal cancer
via targeting TPX2. Bratisl Lek Listy. 121:302–307. 2020.PubMed/NCBI
|
|
12
|
Huo C, Zhang MY, Li R, Zhou XJ, Liu TT, Li
JP, Liu X and Qu YQ: Comprehensive analysis of TPX2-related ceRNA
network as prognostic biomarkers in lung adenocarcinoma. Int J Med
Sci. 17:2427–2439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gomes-Filho SM, Dos Santos EO, Bertoldi
ER, Scalabrini LC, Heidrich V, Dazzani B, Levantini E, Reis EM and
Bassères DS: Aurora A kinase and its activator TPX2 are potential
therapeutic targets in KRAS-induced pancreatic cancer. Cell Oncol
(Dordr). 43:445–460. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang P, Shen K, Wang X, Song H, Yue Y and
Liu T: TPX2 regulates tumor growth in human cervical carcinoma
cells. Mol Med Rep. 9:2347–2351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shigeishi H, Ohta K, Hiraoka M, Fujimoto
S, Minami M, Higashikawa K and Kamata N: Expression of TPX2 in
salivary gland carcinomas. Oncol Rep. 21:341–344. 2009.PubMed/NCBI
|
|
16
|
Cates JMM: Simple staging system for
osteosarcoma performs equivalently to the AJCC and MSTS systems. J
Orthop. 36:2802–2808. 2018.PubMed/NCBI
|
|
17
|
Mu J, Fan L, Liu D and Zhu D:
Overexpression of shugoshin1 predicts a poor prognosis for prostate
cancer and promotes metastasis by affecting epithelial-mesenchymal
transition. Onco Targets Ther. 12:1111–1118. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Joko R, Yamada D, Nakamura M, Yoshida A,
Takihira S, Takao T, Lu M, Sato K, Ito T, Kunisada T, et al: PRRX1
promotes malignant properties in human osteosarcoma. Transl Oncol.
14:1009602021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tian W, Li Y, Zhang J, Li J and Gao J:
Combined analysis of DNA methylation and gene expression profiles
of osteosarcoma identified several prognosis signatures. Gene.
650:7–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cai Y, Mei J, Xiao Z, Xu B, Jiang X, Zhang
Y and Zhu Y: Identification of five hub genes as monitoring
biomarkers for breast cancer metastasis in silico. Hereditas.
156:202019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsu PK, Chen HY, Yeh YC, Yen CC, Wu YC,
Hsu CP, Hsu WH and Chou TY: TPX2 expression is associated with cell
proliferation and patient outcome in esophageal squamous cell
carcinoma. J Gastroenterol. 49:1231–1240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao G, Liang X and Ma W: Sinomenine
restrains breast cancer cells proliferation, migration and invasion
via modulation of miR-29/PDCD-4 axis. Artif Cells Nanomed
Biotechnol. 47:3839–3846. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Q, Geng P, Shi L, Wang Q and Wang P:
miR-29 promotes osteosarcoma cell proliferation and migration by
targeting PTEN. Oncol Lett. 17:883–890. 2019.PubMed/NCBI
|
|
25
|
Ma HZ, Wang J, Shi J, Zhang W and Zhou DS:
MicroRNA-29c-3p inhibits osteosarcoma cell proliferation through
targeting PIK3R3. Eur Rev Med Pharmacol Sci. 24:2239–2247.
2020.PubMed/NCBI
|
|
26
|
Song YZ and Li JF: Circular RNA
hsa_circ_0001564 regulates osteosarcoma proliferation and apoptosis
by acting miRNA sponge. Biochem Biophys Res Commun. 495:2369–2375.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yao L, Yang L, Song H, Liu T and Yan H:
MicroRNA miR-29c-3p modulates FOS expression to repress EMT and
cell proliferation while induces apoptosis in TGF-β2-treated lens
epithelial cells regulated by lncRNA KCNQ1OT1. Biomed Pharmacother.
129:1102902020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li H, Zhang Q, Wu Q, Cui Y, Zhu H, Fang M,
Zhou X, Sun Z and Yu J: Interleukin-22 secreted by
cancer-associated fibroblasts regulates the proliferation and
metastasis of lung cancer cells via the PI3K-Akt-mTOR signaling
pathway. Am J Transl Res. 11:4077–4088. 2019.PubMed/NCBI
|
|
29
|
Yun WK, Hu YM, Zhao CB, Yu DY and Tang JB:
HCP5 promotes colon cancer development by activating AP1G1 via
PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 23:2786–2793.
2019.PubMed/NCBI
|
|
30
|
Huang DH, Jian J, Li S, Zhang Y and Liu
LZ: TPX2 silencing exerts anti-tumor effects on hepatocellular
carcinoma by regulating the PI3K/AKT signaling pathway. Int J Mol
Med. 44:2113–2122. 2019.PubMed/NCBI
|
|
31
|
Wang F, Zhao W, Gao Y, Zhou J, Li H, Zhang
G, Guo D, Xie C, Li J, Yin Z and Zhang J: CDK5-mediated
phosphorylation and stabilization of TPX2 promotes hepatocellular
tumorigenesis. J Exp Clin Cancer Res. 38:2862019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen M, Zhang H, Zhang G, Zhong A, Ma Q,
Kai J, Tong Y, Xie S, Wang Y, Zheng H, et al: Targeting TPX2
suppresses proliferation and promotes apoptosis via repression of
the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in
breast cancer. Biochem Biophys Res Commun. 507:74–82. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Redlak MJ and Miller TA: Targeting
PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to
deoxycholate-induced apoptosis. Dig Dis Sci. 56:323–329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nelson AC, Lyons TR, Young CD, Hansen KC,
Anderson SM and Holt JT: AKT regulates BRCA1 stability in response
to hormone signaling. Mol Cell Endocrinol. 319:129–142. 2010.
View Article : Google Scholar : PubMed/NCBI
|
